参考文献/References:
[1] Libby P, Lichtman AH, Hansson GK. Immune effector
mechanisms implicated in atherosclerosis: from mice to
humans [J]. Immunity, 2013, 38(6): 1092-1104.
[2] O'Donnell VB, Murphy RC, Watson SP. Platelet lipidomics:
modern day perspective on lipid discovery and characteri-
zation in platelets [J]. Circ Res, 2014, 114(7): 1185-1203.
[3] Yang D, Yang W, Zhang Q, et al. Migration of gastric cancer
cells in response to lysophosphatidic acid is mediated by
LPA receptor 2 [J]. Oncol Lett, 2013, 5(3): 1048-1052.
[4] 余雪琛,张元珍,陈慧君. 溶血磷脂酸通过Rac的活化诱
导卵巢癌细胞的侵袭转移 [J]. 中华肿瘤杂志,2015,37
(2):95-100.
[5] Schober A, Siess W. Lysophosphatidic acid in atherosclero-
tic diseases [J]. Br J Pharmacol, 2012, 167(3): 465-482.
[6] Morris AJ, Smyth SS. Lysophosphatidic acid in cardiovas-
cular disease: seeing is believing [J]. J Lipid Res, 2013, 54
(5): 1153-1155.
[7] Lin YT, Verma A, Hodgkinson CP. Toll-like receptors and
human disease: lessons from single nucleotide polymor-
phisms [J]. Curr Genomics, 2012, 13(8): 633-645.
[8] Zhao M, Zhou A, Xu L, et al. The role of TLR4-mediated
PTEN/PI3K/AKT/NF-κB signaling pathway in neuroinfla-
mmation in hippocampal neurons [J]. Neuroscience, 2014,
269: 93-101.
[9] Navi A, Patel H, Shaw S, et al. Therapeutic role of Toll-like
receptor modification in cardiovascular dysfunction [J].
Vascul Pharmaco, 2013, 58(3): 231-239.
[10] Jeong E, Lee JY. Intrinsic and extrinsic regulation of innate
immune receptors [J]. Yonsei Med J, 2011, 52: 379-392.